Download

Bristol-Myers Squibb Co.

Bristol-Myers Squibb accompanies its voluntary licensing activities with full technology transfer related to the manufacturing, testing, packaging and storage of the active pharmaceutical ingredient (API) in its second-line antiretroviral Reyatez.

Since Access to Medicine Index 2008 was published, Bristol-Myers Squibb has discontinued its project with Medicines for Malaria Venture (MMV) for its investigative anti-malarial candidate (protein franesyl-transferase inhibitors).
As part of its flagship program ‘Secure the Future’, Bristol-Myers Squibb launched a technical assistance program in 2008, which provides technical assistance to governments and non-governmental organizations to increase support for HIV/AIDS care in seven African countries.
During the period of analysis the company attempted to block the registration of its products by generics companies in India through the Indian courts based on patent-registration linkage arguments. The company’s claim was rejected by the Indian court.

Bristol-Myers Squibb is below average in the development and disclosure of its ATM program objectives and reporting on key performance indicators related to its ATM initiatives.
Bristol-Myers Squibb does not disclose its financial contributions to third parties in the Index Countries; this limits its “Public Policy and Market Influence” performance.
Bristol-Myers Squibb has low disclosure on areas such as channels (private and/or public) through which equitable pricing is offered and key performance measures such as number of doses sold within different price tiers.
The company has little engagement in research collaborations such as product development partnerships (PDPs) for the Index Diseases (e.g. research for neglected tropical diseases). Its R&D focus is limited to HIV/AIDS.